Skip to main content

Table 5 Completion rates for combined trial arms among regions a

From: Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

Study program Treatment group North America Western Europe Australia/South Africa Japan Asia Eastern Europe/Russia South America/Mexico
IDENTITY Placebo 291 (76.4)EE 162 (81.4)EE 37 (80.4) 99 (90.0)EE 79 (79.8) 79 (59.4) 70 (81.4)
Semagacestat 140 mg PO 198 (50.8) 129 (60.9) 29 (53.7) 69 (64.5) 58 (60.4) 69 (48.9) 31 (37.8)
EXPEDITION Placebo 325 (72.1) 163 (76.5) 32 (84.2) 71 (87.7) 59 (84.3) 38 (61.3) 82 (74.6)
Solanezumab 400 mg IV 303 (67.8)JP 175 (80.7) 35 (76.1) 89 (89.0) 57 (87.7) 43 (75.4) 74 (77.9)
  1. aData are presented as count (%). EE = P < 0.01 vs Eastern Europe; JP = P < 0.01 vs Japan; IV = Intravenously; PO = By mouth.